Concepedia

James Whiteaker

JW

11

Publications

1.2K

Citations

11

H-Index

2013

Active since

Affiliations

AstraZeneca (United States)(Current)

AstraZeneca (India)

AstraZeneca (United Kingdom)

TB Alliance

James Whiteaker is an author at AstraZeneca (United States) specializing in drug resistance, medicine, and drug discovery.

Top concepts

Publications per year

2013–2017

11

Publications

11

The Resistome of Pseudomonas aeruginosa in Relationship to Phenotypic Susceptibility

Veronica N. Kos, Maxime Déraspe, Robert E. McLaughlin et al. · Antimicrobial Agents and Chemotherapy · 2014 · 277 citations · Full text

Azaindoles: Noncovalent DprE1 Inhibitors from Scaffold Morphing Efforts, Kill Mycobacterium tuberculosis and Are Efficacious <i>in Vivo</i>

Pravin S. Shirude, Radha Krishan Shandil, C Sadler et al. · Journal of Medicinal Chemistry · 2013 · 161 citations

, , +22

Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in <i>Pseudomonas aeruginosa</i> strains containing derepressed AmpC

Sushmita D. Lahiri, Grant K. Walkup, James Whiteaker et al. · Journal of Antimicrobial Chemotherapy · 2015 · 124 citations · Full text

Discovery of Imidazo[1,2-<i>a</i>]pyridine Ethers and Squaramides as Selective and Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthesis

Subramanyam J. Tantry, Shankar D. Markad, Vikas Shinde et al. · Journal of Medicinal Chemistry · 2017 · 121 citations

, , +18

4-Aminoquinolone Piperidine Amides: Noncovalent Inhibitors of DprE1 with Long Residence Time and Potent Antimycobacterial Activity

Maruti Naik, Vaishali Humnabadkar, Subramanyam J. Tantry et al. · Journal of Medicinal Chemistry · 2014 · 93 citations · Full text

Rows per page

1–5 of 11